Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
Authors:
- S. MaurySMS. Maury
- F. HuguetFHF. Huguet
- T. LeguayTLT. Leguay
- F. LacombeFLF. Lacombe
- M. MaynadieMMM. Maynadie
- S. GirardSGS. Girard
- A. de LabartheALA. de Labarthe
- E. KuhleinEKE. Kuhlein
- E. RaffouxERE. Raffoux
- X. ThomasXTX. Thomas
- P. ChevallierPCP. Chevallier
- A. BuzynABA. Buzyn
- 22 September 2009
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (2) , 324-328
Abstract
The prognostic significance of CD20 expression in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has been mostly studied in children and yielded conflicting results. In 143 adults with Philadelphia chromosome-negative BCP-ALL treated in the multicentric GRAALL 2003 trial, CD20 positivity over 20% was observed in 32% of patients. While not influencing complete remission achievement, CD20 expression was associated with a higher cumulative incidence of relapse (CIR) at 42 months (P=0.04), independently of the ALL high-risk subset (P=0.025). Notably, the negative impact of CD20 expression on CIR was only observed in patients with a white blood cell count (WBC) over 30×109/L (P=0.006), while not in those with a lower WBC. In the former subgroup, this impact translated into lower event-free survival (15% vs. 59% at 42 months, P=0.003). CD20 expression thus appears to be associated with a worse outcome, which reinforces the interest of evaluating rituximab combined to chemotherapy in CD20-positive adult BCP-ALL. ClinicalTrials.gov ID, NCT00222027.Keywords
This publication has 20 references indexed in Scilit:
- Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaBlood, 2009
- A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocolBlood, 2005
- Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospectsAnnals of Hematology, 2003
- Induction of Long-Term Remission of a Relapsed Childhood B–Acute Lymphoblastic Leukemia With Rituximab Chimeric Anti-CD20 Monoclonal Antibody and Autologous Stem Cell TransplantationJournal of Pediatric Hematology/Oncology, 2003
- Antibody-based therapy of human leukemiaCurrent Opinion in Hematology, 2002
- Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemiaBone Marrow Transplantation, 2001
- Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) – a report of the Children’s Cancer GroupLeukemia, 1999
- Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group StudyBlood, 1997
- Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).1995
- Multinomial regression models based on continuation ratiosStatistics in Medicine, 1988